Personalized therapies in psychiatry: promises, pitfalls and perspectives

Journal of Neural Transmission

Volumn 122, Issue 1, 2015, Pages

  Domschke, Katharina ^a   Müller, Daniel J ^b,c   Serretti, Alessandro ^d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM; MICRORNA; PSYCHOTROPIC AGENT;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL FEATURE; COPY NUMBER VARIATION; DEPRESSION; DNA METHYLATION; DRUG RESPONSE; EDITORIAL; EPIGENETICS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MELANCHOLIA; MENTAL DISEASE; MENTAL HEALTH CARE; MOLECULAR IMAGING; NEUROIMAGING; NEUROPSYCHIATRY; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; METHODS; PSYCHIATRY; TRENDS;

HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; PSYCHIATRY;

EID: 84938633621     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1340-x     Document Type: Editorial

References (11)

1. Burton R (1651) The anatomy of melancholy. The New York Review of Books, New York
2. Domschke K, Dannlowski U (2010) Imaging genetics of anxiety disorders. NeuroImage 53:822–831
3. Drozda K, Müller DJ, Bishop JR (2014) Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy 34:166–184
4. Gerretsen P, Müller DJ, Tiwari A, Mamo D, Pollock BG (2009) The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin Neurosci 11:363–376
5. Goldman D, Domschke K (2014) Making sense of deep sequencing. Int J Neuropsychopharmacol 17:1717–1725
6. Kalow W (2007) Personalized medicine—some thoughts. McGill J Med 10:58
7. Kennedy SH, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C (2012) The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des 18:5976–5989
8. Menke A, Binder EB (2014) Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin Neurosci 16:395–404
9. Müller DJ, Kekin I, Kao AC, Brandl EJ (2013) Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry 25:554–571
10. Olgiati P, Bajo E, Bigelli M, Montgomery S, Serretti A, C.E.A.P (Cost-Effectiveness Analysis on Psychiatric Disorders)-group (2013) Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Eur Neuropsychopharmacol 23:1739–1746
11. Serretti A, Artioli P (2006) Ethical problems in pharmacogenetic studies of psychiatric disorders. Pharmacogenomics J6:289–295